Quoin Pharmaceuticals/$QNRX
13:30
09:10
04:45
00:25
20:00
1D1W1MYTD1Y5YMAX
About Quoin Pharmaceuticals
Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.
Ticker
$QNRX
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
4
ISIN
US74907L4095
Website
QNRX Metrics
BasicAdvanced
$5M
-
-$39.35
1.60
-
Price and volume
Market cap
$5M
Beta
1.6
52-week high
$9.90
52-week low
$5.01
Average daily volume
366K
Financial strength
Current ratio
2.574
Quick ratio
2.379
Long term debt to equity
36.682
Total debt to equity
46.808
Management effectiveness
Return on assets (TTM)
-47.40%
Return on equity (TTM)
-138.82%
Valuation
Price to book
0.85
Price to tangible book (TTM)
0.92
Price to free cash flow (TTM)
-0.251
Growth
Earnings per share change (TTM)
-83.06%
QNRX News
AllArticlesVideos
Quoin Pharmaceuticals Announces European Medicines Agency (EMA) Grants Orphan Drug Designation for QRX003 for the Treatment of Netherton Syndrome
GlobeNewsWire·2 weeks ago
Quoin Pharmaceuticals Announces Initial Positive Clinical Data for QRX003 from Pediatric Peeling Skin Syndrome Study
GlobeNewsWire·3 weeks ago
Quoin Pharmaceuticals Releases Second Episode of its “Living with Netherton” Series, as part of its ongoing NETHERTON NOW awareness campaign
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Quoin Pharmaceuticals stock?
Quoin Pharmaceuticals (QNRX) has a market cap of $5M as of June 02, 2025.
What is the P/E ratio for Quoin Pharmaceuticals stock?
The price to earnings (P/E) ratio for Quoin Pharmaceuticals (QNRX) stock is 0 as of June 02, 2025.
Does Quoin Pharmaceuticals stock pay dividends?
No, Quoin Pharmaceuticals (QNRX) stock does not pay dividends to its shareholders as of June 02, 2025.
When is the next Quoin Pharmaceuticals dividend payment date?
Quoin Pharmaceuticals (QNRX) stock does not pay dividends to its shareholders.
What is the beta indicator for Quoin Pharmaceuticals?
Quoin Pharmaceuticals (QNRX) has a beta rating of 1.6. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.